- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 160168, 10 pages
Expression Profiling and Proteomic Analysis of JIN Chinese Herbal Formula in Lung Carcinoma H460 Xenografts
1College of Basic Medicine and School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210029, China
2Zhejiang California International Nanosystems Institute, Zhejiang University, Hangzhou 310058, China
3School of Chinese Medicine, Hong Kong Baptist University, Hong Kong
4Department of Pharmacology and Winship Cancer Institute, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA
Received 28 March 2013; Revised 8 July 2013; Accepted 17 July 2013
Academic Editor: Aiping Lu
Copyright © 2013 Luyu Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- W. Y. Jiang, “Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science,” Discovery Medicine, vol. 5, no. 29, pp. 455–461, 2005.
- A. I. Nesvizhskii, A. Keller, E. Kolker, and R. Aebersold, “A statistical model for identifying proteins by tandem mass spectrometry,” Analytical Chemistry, vol. 75, no. 17, pp. 4646–4658, 2003.
- A. Keller and D. Shteynberg, “Software pipeline and data analysis for MS/MS proteomics: the trans-proteomic pipeline,” Methods in Molecular Biology, vol. 694, pp. 169–189, 2011.
- P. G. A. Pedrioli, “Trans-proteomic pipeline: a pipeline for proteomic analysis,” Methods in Molecular Biology, vol. 604, pp. 213–238, 2010.
- J. G. Booth, K. E. Eilertson, P. D. B. Olinares, and H. Yu, “A bayesian mixture model for comparative spectral count data in shotgun proteomics,” Molecular and Cellular Proteomics, vol. 10, no. 8, 2011.
- B. R. Zeeberg, W. Feng, G. Wang et al., “GoMiner: a resource for biological interpretation of genomic and proteomic data,” Genome Biology, vol. 4, no. 4, p. R28, 2003.
- B. R. Zeeberg, H. Qin, S. Narasimhan et al., “High-throughput GoMiner, an “industrial-strength” integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID),” BMC Bioinformatics, vol. 6, article 168, 2005.
- E. M. Algar, A. Muscat, V. Dagar et al., “Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors,” PLoS ONE, vol. 4, no. 2, Article ID e4482, 2009.
- J. Park, K. Kim, E.-J. Lee et al., “Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 43, pp. 17028–17033, 2007.
- S. J. Freemantle and E. Dmitrovsky, “Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention,” Cancer Prevention Research, vol. 3, no. 12, pp. 1513–1518, 2010.
- H. Lemjabbar-Alaoui, V. Dasari, S. S. Sidhu et al., “Wnt and hedgehog are critical mediators of cigarette smoke-induced lung cancer,” PLoS ONE, vol. 1, no. 1, article e93, 2006.
- J. W. Neal and L. V. Sequist, “Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh,” Current Treatment Options in Oncology, vol. 11, no. 1-2, pp. 36–44, 2010.
- Y. Katoh and M. Katoh, “Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation,” Current Molecular Medicine, vol. 9, no. 7, pp. 873–886, 2009.
- J. Mazieres, B. He, L. You, Z. Xu, and D. M. Jablons, “Wnt signaling in lung cancer,” Cancer Letters, vol. 222, no. 1, pp. 1–10, 2005.
- S. Lu, Z. Tan, M. Wortman, S. Lu, and Z. Dong, “Regulation of heat shock protein 70-1 expression by androgen receptor and its signaling in human prostate cancer cells,” International Journal of Oncology, vol. 36, no. 2, pp. 459–467, 2010.
- S. K. Calderwood, M. A. Khaleque, D. B. Sawyer, and D. R. Ciocca, “Heat shock proteins in cancer: chaperones of tumorigenesis,” Trends in Biochemical Sciences, vol. 31, no. 3, pp. 164–172, 2006.
- S. A. Eccles, A. Massey, F. I. Raynaud et al., “NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis,” Cancer Research, vol. 68, no. 8, pp. 2850–2860, 2008.
- S. Tsutsumi, B. Scroggins, F. Koga et al., “A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion,” Oncogene, vol. 27, no. 17, pp. 2478–2487, 2008.
- M. Daugaard, M. Rohde, and M. Jäättelä, “The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions,” FEBS Letters, vol. 581, no. 19, pp. 3702–3710, 2007.
- M. P. Mayer and B. Bukau, “Hsp70 chaperones: cellular functions and molecular mechanism,” Cellular and Molecular Life Sciences, vol. 62, no. 6, pp. 670–684, 2005.